Single-Dose Treatment With Vesicular Stomatitis Virus–Based Ebola Virus Vaccine Expressing Ebola Virus–Specific Artificial Micro-RNA Does Not Protect Mice From Lethal Disease
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiad121 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Kyle L O'Donnell und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilt…. Hauptthemen laut MEDLINE: Ebolavirus, Hemorrhagic Fever, Ebola, Ebola Vaccines, Vesicular Stomatitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Abstract (Originalsprache)
Although significant progress has been made in the development of therapeutics against Ebola virus (EBOV), we sought to expand upon existing strategies and combine an RNA interference–based intervention with the approved vesicular stomatitis virus–based Ebola virus (VSV-EBOV) vaccine to conjointly treat and vaccinate patients during an outbreak. We constructed VSV-EBOV vectors expressing artificial micro-RNAs (amiRNAs) targeting sequences of EBOV proteins. In vitro experiments demonstrated a robust decrease in EBOV replication using a minigenome system and infectious virus. For in vivo evaluation, mouse-adapted EBOV–infected CD-1 mice were treated 24 hours after infection with a single dose of the VSV-EBOV amiRNA constructs. We observed no difference in disease progression or survival compared to the control-treated mice. In summary, while amiRNAs decrease viral replication in vitro, the effect is not sufficient to protect mice from lethal disease, and this therapeutic approach requires further optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
- Laboratory for Integrative Cell and Infection Biology, Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald, Germany.
ORCID-Profile: Heinz Feldmann, Thomas Hoenen
Förderung
- NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
O'Donnell, K. L., Callison, J., Feldmann, H., Hoenen, T., & Marzi, A. (2023). Single-Dose Treatment With Vesicular Stomatitis Virus–Based Ebola Virus Vaccine Expressing Ebola Virus–Specific Artificial Micro-RNA Does Not Protect Mice From Lethal Disease. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad121
Vancouver
O'Donnell KL, Callison J, Feldmann H, Hoenen T, Marzi A. Single-Dose Treatment With Vesicular Stomatitis Virus–Based Ebola Virus Vaccine Expressing Ebola Virus–Specific Artificial Micro-RNA Does Not Protect Mice From Lethal Disease. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad121
BibTeX
@article{ODonnell2023,
author = {O'Donnell, Kyle L and Callison, Julie and Feldmann, Heinz and Hoenen, Thomas and Marzi, Andrea},
title = {Single-Dose Treatment With Vesicular Stomatitis Virus–Based Ebola Virus Vaccine Expressing Ebola Virus–Specific Artificial Micro-RNA Does Not Protect Mice From Lethal Disease},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiad121}
}
EUVIMED